摘要
目的探讨乙型肝炎(下称乙肝)患者血浆与血清中游离HBV-DNA含量有无差异。方法采用实时荧光定量基因扩增技术,抽取乙肝患者静脉血2mL,其中1mL注入普通真空采血管,另1mL注入含EDTA-Na2抗凝剂的真空采血管内,并混匀,4h内分离血清和血浆,对二者同时进行HBV-DNA定量检测。结果127例乙肝患者血浆和血清标本阳性率分别为74.8%(95/127)和72.4%(92/127),差异无统计学意义(χ2=0.182,P>0.05);两种标本检测为阳性者其含量差异无统计学意义(t=1.365,P>0.05)。结论血浆和血清标本均可用于乙肝患者HBV-DNA定量检测。但由于血液在凝固过程中纤维蛋白的收缩及红细胞的聚集,可能会将血液中少量乙肝病毒颗粒包裹在一起形成凝块,使血清中HBV含量略低于血液中的实际含量,加上抗凝血标本可快速分离出血浆,方便实验室工作,故建议临床工作中做HBV等病毒定量检测最好采用血浆标本。
Objective To investigate the difference of free HBV-DNA content in serum and plasma in patients with hepatits B. Methods Venous blood 2 mL was collected from each patient with hepatitis B, half emptied into the ordinary vacuum blood vessel, half into the vacuum blood vessel containing decoagulant EDTA-Na2. After misce ben- e, serum and plasma were separated during 4 h. Real-time fluorescence quantitative polymerase chain reaction (FQPCR) was applied to quantitatively detecting HBV-DNA. Results The HBV-DNA positive rates were 74.8% (95/ 127) and 72. 4% (92/127) in plasma and serum samples from 127 patients with hepatitis B respectively, and the difference wasn't significant (χ^2=0. 182, P〉0.05). There wasn't statistical difference of H BV-DNA content between two kind of positive samples (t=1. 365 ,P〉0.05). Conclusion The sample of plasma and serum can be used to quantitatively detect HBV-DNA for patients with hepatitis B. Yet due to contraction of fibrin and assembling of erythrocyte in the blood coagulating process, a few HBV virus particles wrap up to coagulum leading to serum HBV content a little lower than actual content. Moreover, plasma can be separated rapidly from anticoagulated blood samples, which is convenient to laboratory. Therefore it is suggested that plasma samples should be adopted preferentially in HBV quantitatively detection.
出处
《检验医学与临床》
CAS
2008年第8期462-463,共2页
Laboratory Medicine and Clinic